Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

Study identifier:2993-115

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Twice Daily in Subjects With Type 2 Diabetes Mellitus Treated With Metformin and a Sulfonylurea

Medical condition

Diabetes Mellitus, Non-Insulin-Dependent

Phase

Phase 3

Healthy volunteers

No

Study drug

AC2993, AC2993, Placebo, Placebo

Sex

All

Actual enrollment

734

Study type

Interventional

Age

16 Years - 75 Years

Date

Study Start Date: 01 May 2002
Primary Completion Date: 01 Aug 2003
Study Completion Date: 01 Aug 2003

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria